 |
|
Gene Therapy and Vein Graft Patency in Coronary Artery Bypass Graft Surgery
Vincent R. Conti, MD;
Glenn C. Hunter, MD
JAMA. 2005;294:2495-2497. Published online November 13, 2005 (doi:10.1001/jama.294.19.jed50077).
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
A major and much-needed advance for cardiac surgeons and patients requiring coronary artery bypass graft (CABG) surgery would be the availability of an easily applied intervention that would improve long-term patency rates for saphenous vein grafts to those achieved with internal thoracic artery grafts. With newer endoscopic techniques, the saphenous vein can be harvested with minimal trauma and without compromising short-term patency rates.1-2 While saphenous vein grafts are the easiest conduits to use technically, especially for sequential grafting, the internal thoracic artery, with its excellent long-term patency (especially when used to the left anterior descending vessel), will remain the preferred primary conduit in the vast majority of cases.
Saphenous vein graft failure has a trimodal distribution. Early failure occurs within the first 1 to 2 months, probably from primary thrombosis due to technical factors, poor runoff into small or severely diseased distal . . . [Full Text of this Article]
Author Affiliation: Department of Surgery, University of Texas Medical Branch, Galveston.
RELATED ARTICLE
Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial
PREVENT IV Investigators
JAMA. 2005;294(19):2446-2454.
ABSTRACT
| FULL TEXT
|
